As small molecule complexity increases, early-stage development faces new challenges that demand innovative solutions. At Lonza Advanced Synthesis the continuous flow process is integrated into early phase development, allowing for optimization of chemical processes from pre-clinical work all the way to Phase III.
In this article, Lonza’s experts explain why traditional batch processing can hinder innovation and elevate risk, and how continuous flow enables improvements in speed, safety, and product consistency. With a proven track record of 50 projects and 50 peer-reviewed publications, they also highlight capabilities beyond flow chemistry, including AI-enabled route scouting and their cutting-edge ‘mini-mono plant’ technology.